Apyx Medical (APYX) 10-Q/A 8 May 20 2018 Q3 Quarterly report (amended) Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Oct. 29, 2018
Document And Entity Information
Entity Registrant Name	APYX MEDICAL CORP
Entity Central Index Key	0000719135
Document Type	10-Q/A
Document Period End Date	Sep. 30, 2018
Amendment Flag	true
Amendment Description	Explanatory Note As disclosed in Item 4.02 of the Company’s current report on Form 8-K filed with the U.S Securities and Exchange Commission ("SEC") on March 16, 2020, on March 12, 2020 the Audit Committee of the Board of Directors of Apyx Medical Corporation (formerly known as Bovie Medical Corporation) (the “Company”) concluded, after review and discussion with management, that the Company’s financial statements as of and for the three and nine months ended September 30, 2018 ( the “Financial Statements”) should no longer be relied upon. This Amendment No. 1 to on the Company’s Form 10-Q (this “Form 10-Q/A") amends and restates certain items noted below in the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2018, as originally filed with the Securities and Exchange Commission on November 2, 2018 (the “Original Filing”). This Form 10-Q/A amends the Original Filing to reflect the correction of an error in the previously reported financial statements related to the Company’s failure to properly collect and remit employee income and payroll taxes, and remit the employer portion of payroll taxes, resulting from the exercise of non-qualified stock options. In addition, the Company has also corrected other minor items primarily related to the appropriate cutoff of transactions at the balance sheet date and the duplicate recording of a State income tax payment. See Note 2 to the Condensed Consolidated Financial Statements included in Item 1 for additional information and a reconciliation of the previously reported amounts to the restated amounts. For the convenience of the reader, this Form 10-Q/A sets forth the Original Filing, as amended, in its entirety; however, this Form 10-Q/A amends and restates only the following financial statements and disclosures that were impacted from the correction of the errors: Part I, Item 1 - Financial Statements Part I, Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations Part II, Item 6 - Exhibits Signatures The Company’s Chief Executive Officer and Chief Financial Officer have provided new certifications dated as of the date of this filing in connection with this Form 10-Q/A(Exhibits 31.1, 31.2, 32.1 and 32.2),and the Company has provided its revised audited consolidated financial statements formatted in Extensible Business Reporting Language (XBRL) in Exhibit 101. Except as described above, no other changes have been made to the Original Filing. This Form 10-Q/A speaks as of the date of the Original Filing and does not reflect events that may have occurred after the date of the Original Filing, or modify or update any disclosures that may have been affected by subsequent events. The Company is also concurrently filing an amended Quarterly Report for the three months ended March 31, 2019 to restate their previously issued interim financial statements due to the accounting errors described above, as well as some additional errors identified with an impact to that period.
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		33,203,517
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Small Business	true
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2018

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 40,663	$ 9,949
Restricted cash	0	719
Short term investments	55,480	0
Trade accounts receivable, net of allowance of $311 and $204	4,139	4,857
Inventories, net	6,037	4,274
Prepaid expenses and other current assets	627	433
Current assets of discontinued operations	0	2,315
Total current assets	106,946	22,547
Property and equipment, net	5,842	6,033
Purchased technology and license rights, net	32	67
Goodwill	185	185
Deposits	46	92
Other assets	122	67
Non-current assets of discontinued operations	0	1,997
Total assets	113,173	30,988
Current liabilities:
Accounts payable	2,348	1,583
Accrued severance and related	95	1,242
Accrued payroll	163	447
Current portion of mortgage note payable	0	239
Accrued expenses and other current liabilities	19,830	214
Current liabilities of discontinued operations	0	2,248
Total current liabilities	22,436	5,973
Mortgage note payable, net of current portion	0	2,455
Related party note payable	140	140
Deferred tax liability	0	368
Derivative liabilities	0	20
Total liabilities	22,576	8,956
STOCKHOLDERS’ EQUITY
Common stock, $0.001 par value; 75,000,000 shares authorized; 33,763,019 issued and 33,620,444 outstanding as of September 30, 2018 and 75,000,000 shares authorized; 33,021,170 issued and 32,878,091 outstanding as of December 31, 2017, respectively	33	33
Additional paid-in capital	51,798	50,495
Retained earnings (accumulated deficit)	38,766	(28,496)
Total stockholders’ equity	90,597	22,032
Total liabilities and stockholders’ equity	$ 113,173	$ 30,988

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 311	$ 204
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	33,763,019	33,021,170
Common stock, shares outstanding (in shares)	33,620,444	32,878,091

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	Aug. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Sales		$ 3,672	$ 2,651	$ 10,760	$ 6,576
Cost of sales		1,151	738	3,490	2,314
Gross profit		2,521	1,913	7,270	4,262
Other costs and expenses:
Research and development		613	487	1,890	1,600
Professional services		628	421	1,815	1,291
Salaries and related costs		2,170	1,826	5,785	6,016
Selling, general and administrative		1,898	2,012	6,221	6,003
Total other costs and expenses		5,309	4,746	15,711	14,910
Loss from operations		(2,788)	(2,833)	(8,441)	(10,648)
Interest income (expense), net		105	(36)	33	(103)
Other losses		(868)	0	(868)	0
Change in fair value of derivative liabilities		0	(69)	20	57
Total other expense, net		(763)	(105)	(815)	(46)
Loss from continuing operations before income taxes		(3,551)	(2,938)	(9,256)	(10,694)
Income tax (benefit) expense		(2,408)	6	(2,384)	15
Net loss from continuing operations		(1,143)	(2,944)	(6,872)	(10,709)
Income from discontinued operations, net of tax		540	1,699	5,062	6,471
Gain on sale of the Core Business, net of tax	$ 69,072	69,072	0	69,072	0
Total income from discontinued operations, net of tax		69,612	1,699	74,134	6,471
Net income (loss)		$ 68,469	$ (1,245)	$ 67,262	$ (4,238)
Loss per share from continuing operations
Loss per share from continuing operations, basic		$ (0.03)	$ (0.09)	$ (0.21)	$ (0.35)
Loss per share from continuing operations, diluted		(0.03)	(0.09)	(0.21)	(0.35)
Income per share from discontinued operations
Income per share from discontinued operations, basic		2.09	0.05	2.25	0.21
Income per share from discontinued operations, diluted		1.99	0.05	2.19	0.21
Income (loss) per share
Income (loss) per share, basic		2.06	(0.04)	2.04	(0.14)
Income (loss) per share, diluted		$ 1.96	$ (0.04)	$ 1.98	$ (0.14)
Weighted average number of shares outstanding - basic (in shares)		33,275	31,078	33,014	30,932
Weighted average number of shares outstanding - dilutive (in shares)		34,934	31,078	33,952	30,932

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Preferred Stock	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)
Beginning balance (in shares) at Dec. 31, 2016		976	30,860
Beginning balance, amount at Dec. 31, 2016	$ 26,223	$ 1	$ 31	$ 49,625	$ (23,434)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Options exercised (in shares)			21
Options exercised	275			275
Conversion of Series B convertible preferred to common stock (in shares)		(976)	1,951
Conversion of Series B convertible preferred to common stock	0	$ (1)	$ 2	(1)
Stock based compensation	532			532
Stock issued to acquire options and warrants	(275)			(275)
Net income (loss)	(4,238)				(4,238)
Ending balance, amount at Sep. 30, 2017	22,517	$ 0	$ 33	50,156	(27,672)
Ending balance (in shares) at Sep. 30, 2017		0	32,832
Beginning balance (in shares) at Dec. 31, 2017		0	32,878
Beginning balance, amount at Dec. 31, 2017	22,032	$ 0	$ 33	50,495	(28,496)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Options exercised (in shares)			1,278
Options exercised	3,103			3,103
Warrant exercised (in shares)			40
Warrants exercised	95			95
Stock based compensation	1,238			1,238
Stock issued to acquire options and warrants (in shares)			(576)
Stock issued to acquire options and warrants	(3,133)			(3,133)
Net income (loss)	67,262				67,262
Ending balance, amount at Sep. 30, 2018	$ 90,597	$ 0	$ 33	$ 51,798	$ 38,766
Ending balance (in shares) at Sep. 30, 2018		0	33,620

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities
Net income (loss)	$ 67,262	$ (4,238)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Gain on sale of the Core Business, net of tax	(69,072)	0
Depreciation and amortization	429	527
Gain on disposal of property and equipment, net	0	3
Stock based compensation	1,238	532
Change in fair value of derivative liabilities	(20)	(57)
Unrealized gain on short term investments	(47)	0
Provision for allowance for doubtful accounts	123	128
Benefit of deferred taxes	(368)	0
Changes in current assets and liabilities, net of effect of disposition:
Trade receivables	595	528
Prepaid expenses and other assets	(188)	(221)
Inventories	(1,706)	(1,177)
Deposits and other assets	(9)	9
Accounts payable	765	(219)
Accrued expenses and other liabilities	(1,837)	(250)
Net cash used in operating activities	(2,835)	(4,435)
Cash flows from investing activities
Purchases of property and equipment	(203)	(431)
Proceeds from the disposition of Core business	91,095	0
Purchases of marketable securities	(55,433)	0
Net cash from investing activities	35,459	(431)
Cash flows from financing activities
Proceeds from stock options/warrants exercised	65	0
Repayment of mortgage note payable	(2,694)	(179)
Net cash used in financing activities	(2,629)	(179)
Net change in cash, cash equivalents and restricted cash	29,995	(5,045)
Cash, cash equivalents and restricted cash, beginning of period	10,668	15,235
Cash, cash equivalents and restricted cash, end of period	40,663	10,190
Cash paid for:
Interest (income) expense, net	(33)	103
Non cash investing activities:
Cashless exercise of stock options/warrants	$ 3,133	$ 275

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION Unless the context otherwise indicates, the terms “we,” “our,” “us,” “Bovie,” "Apyx," "Company" and similar terms refer to Apyx Medical Corporation (formerly Bovie Medical Corporation) and its consolidated subsidiaries. We reclassified the financial results of the Core business to discontinued operations and from segment results for all periods presented. The accompanying unaudited consolidated financial statements have been prepared based upon SEC rules that permit reduced disclosure for interim periods. For a more complete discussion of significant accounting policies and certain other information, please refer to the financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017. These financial statements reflect all adjustments that are necessary for a fair presentation of results of operations and financial condition for the interim periods shown, including normal recurring accruals and other items. The results for the interim periods are not necessarily indicative of results for the full year.

RESTATEMENT

RESTATEMENT	9 Months Ended
	Sep. 30, 2018
Accounting Changes and Error Corrections [Abstract]
Restatement	RESTATEMENT Throughout 2019, the Company made efforts to remediate its material weaknesses in internal control as of December 31, 2018, including investing in new personnel that have expertise in a broad array of accounting topics. As a result of these investments and remediation efforts, the Company reevaluated the accounting for a broad array of items and discovered numerous immaterial errors. On March 12, 2020, our Management and the Audit Committee of the Board of Directors, following discussion with our predecessor independent registered public accounting firm, concluded that the Company's previously filed financial statements as of and for three and nine months ended September 30, 2018, were no longer able to be relied upon as the result of the aggregation of errors identified by Management and the Company’s new accounting personnel during 2019 related to the following: As identified during preparation of the fiscal year 2019 Form 10-K: • During the first quarter of 2020, while reconciling the 2019 income tax provision back to the corresponding records, we determined that when employees exercised non-qualified stock options, we did not collect and remit the employee’s income and payroll taxes on the exercises and did not accrue and remit the employer portion of payroll taxes. Due to statutory requirements, we have joint and several liability on the amounts that we did not withhold from employees and remit to the proper taxing authorities. While further investigating the issue, we determined that during 2018 we did not report the correct amount of income to employees on their form W-2 for both non-qualified and incentive stock option exercises and misclassified some non-qualified stock option exercises as incentive stock option exercises. ◦ For the three and nine months ended September 30, 2018 and year ended December 31, 2018, the total aggregated impact included an increase of approximately $51,000 to operating expenses, an increase of approximately $713,000 to other losses and an increase to net loss of approximately $764,000 . • Other minor items primarily related to the appropriate cutoff of transactions at the balance sheet date and the duplicate recording of a State income tax payment. ◦ For the three and nine months ended September 30, 2018, the total aggregated impact included an increase of approximately $59,000 to operating expenses, operating loss and net loss. A reconciliation of the originally reported amounts to the restated amounts for the adjustments noted above for each of the affected periods is presented below. Consolidated Balance Sheet as of September 30, 2018: (In thousands) As Originally Reported Adjustments As Restated ASSETS Current assets: Cash and cash equivalents $ 40,663 $ — $ 40,663 Short term investments 55,480 — 55,480 Trade accounts receivable, net 4,080 59 4,139 Inventories, net 6,037 — 6,037 Prepaid expenses and other current assets 627 — 627 Total current assets 106,887 59 106,946 Property and equipment, net 5,842 — 5,842 Purchased technology and license rights, net 32 — 32 Goodwill 185 — 185 Deposits 46 — 46 Other assets 122 — 122 Total assets $ 113,114 $ 59 $ 113,173 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 2,348 $ — $ 2,348 Accrued severance and related 95 — 95 Accrued payroll 163 — 163 Accrued expenses and other current liabilities 19,066 764 19,830 Total current liabilities 21,672 764 22,436 Related party note payable 140 — 140 Total liabilities 21,812 764 22,576 STOCKHOLDERS' EQUITY Common stock, $0.001 par value; 75,000,000 shares authorized; 33,763,019 issued and 33,620,444 outstanding 33 — 33 Additional paid-in capital 51,798 — 51,798 Retained earnings 39,471 (705 ) 38,766 Total stockholders’ equity 91,302 (705 ) 90,597 Total liabilities and stockholders’ equity $ 113,114 $ 59 $ 113,173 Consolidated Statement of Operations for the three months ended September 30, 2018: (In thousands) As Originally Reported Adjustments As Restated Sales $ 3,672 $ — $ 3,672 Cost of sales 1,151 — 1,151 Gross profit 2,521 — 2,521 Other costs and expenses: Research and development 613 — 613 Professional services 628 — 628 Salaries and related costs 2,119 51 2,170 Selling, general and administrative 1,957 (59 ) 1,898 Total other costs and expenses 5,317 (8 ) 5,309 Loss from operations (2,796 ) 8 (2,788 ) Interest income (expense), net 105 — 105 Other losses (155 ) (713 ) (868 ) Total other losses, net (50 ) (713 ) (763 ) Loss from continuing operations before income taxes (2,846 ) (705 ) (3,551 ) Income tax benefit (2,408 ) — (2,408 ) Net loss from continuing operations (438 ) (705 ) (1,143 ) Income from discontinued operations, net of tax 540 — 540 Gain on sale of the Core Business, net of tax 69,072 — 69,072 Total income from discontinued operations, net of tax 69,612 — 69,612 Net income (loss) $ 69,174 $ (705 ) $ 68,469 Loss per share from continuing operations Basic and Diluted $ (0.01 ) $ (0.02 ) $ (0.03 ) Income per share from discontinued operations Basic 2.09 — 2.09 Diluted 1.99 — 1.99 Income (loss) per share from all operations Basic 2.08 (0.02 ) 2.06 Diluted 1.98 (0.02 ) 1.96 Weighted average number of shares outstanding basic 33,275 33,275 33,275 Weighted average number of shares outstanding diluted 34,934 34,934 34,934 Consolidated Statement of Operations for the nine months ended September 30, 2018: (In thousands) As Originally Reported Adjustments As Restated Sales $ 10,760 $ — $ 10,760 Cost of sales 3,490 — 3,490 Gross profit 7,270 — 7,270 Other costs and expenses: Research and development 1,890 — 1,890 Professional services 1,815 — 1,815 Salaries and related costs 5,734 51 5,785 Selling, general and administrative 6,280 (59 ) 6,221 Total other costs and expenses 15,719 (8 ) 15,711 Loss from operations (8,449 ) 8 (8,441 ) Interest income (expense), net 33 — 33 Other losses (155 ) (713 ) (868 ) Change in fair value of derivative liabilities 20 — 20 Total other losses, net (102 ) (713 ) (815 ) Loss from continuing operations before income taxes (8,551 ) (705 ) (9,256 ) Income tax benefit (2,384 ) — (2,384 ) Net loss from continuing operations (6,167 ) (705 ) (6,872 ) Income from discontinued operations, net of tax 5,062 — 5,062 Gain on sale of the Core Business, net of tax 69,072 — 69,072 Total income from discontinued operations, net of tax 74,134 — 74,134 Net income (loss) $ 67,967 $ (705 ) $ 67,262 Loss per share from continuing operations Basic and Diluted $ (0.19 ) $ (0.02 ) $ (0.21 ) Income per share from discontinued operations Basic 2.25 — 2.25 Diluted 2.19 — 2.19 Income (loss) per share from all operations Basic 2.06 (0.02 ) 2.04 Diluted 2.00 (0.02 ) 1.98 Weighted average number of shares outstanding basic 33,014 33,014 33,014 Weighted average number of shares outstanding diluted 33,952 33,952 33,952

DISPOSITION OF THE CORE BUSINES

DISPOSITION OF THE CORE BUSINESS	9 Months Ended
	Sep. 30, 2018
Discontinued Operations and Disposal Groups [Abstract]
DISPOSITION OF THE CORE BUSINESS	DISPOSITION OF THE CORE BUSINESS On August 30, 2018, we closed on a previously disclosed definitive asset purchase agreement with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly-owned subsidiary of Symmetry Surgical Inc. (“Symmetry”), pursuant to which the Company divested and sold the Company's electrosurgical "Core" business segment and related intellectual property, including the Bovie ® brand and trademarks, to Symmetry for gross proceeds of $97 million in cash. In connection with the asset purchase agreement, we entered into a previously disclosed Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement with Symmetry for a four -year term, whereby we will manufacture certain Core products and sell them to Symmetry at agreed upon prices. Any revenue, costs and expenses resulting from this agreement are netted and reported in our Consolidated Statements of Operations as Other gains or losses. Additionally, in connection with the asset purchase agreement, we entered into a previously disclosed Manufacture and Supply Agreement with Symmetry for a ten -year term, whereby we will manufacture certain products and sell them to Symmetry at agreed upon prices. Revenue, costs and expenses resulting from this agreement are reported in our Consolidated Statements as income or loss from operations of our OEM reporting segment. We concluded that the divestiture of the Core business met the criteria for discontinued operations set forth in ASC No. 205, Presentation of Financial Statements . The table below summarizes the cash consideration and the carrying values of disposed assets at the disposition date of August 30, 2018 included as part of discontinued operations: (In thousands) Gross consideration from the sale of the Core Business $ 97,000 Closing and transaction costs 5,905 Net proceeds from sale of the Core Business before taxes $ 91,095 Book value of the Core Business Current assets: Inventories, net 2,195 Prepaid expenses and other current assets 57 Total current assets 2,252 Property and equipment, net of depreciation 375 Brand name and trademark 1,510 Purchased technology and license rights, net of depreciation 112 Total non-current assets 1,997 Total assets $ 4,249 Current liabilities: Accrued inventory liability 2,305 Total current liabilities 2,305 Total book value of the Core Business $ 6,554 Net gain on sale of the Core Business before taxes 84,541 Income tax expense 15,469 Net gain on sale of the Core Business after income taxes $ 69,072

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories are stated at the lower of cost or market. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are allocated to inventory manufactured in-house based upon labor hours. Inventories consisted of the following: (In thousands) September 30, December 31, Raw materials $ 5,032 $ 5,163 Finished goods 1,998 1,024 Gross inventories 7,030 6,187 Less: reserve for obsolescence (993 ) (1,913 ) Net inventories of continuing operations 6,037 4,274 Finished goods of discontinued operations — 2,252 Net inventories of continuing and discontinued operations $ 6,037 $ 6,526

INTANGIBLE ASSETS

INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	INTANGIBLE ASSETS Intangible assets consisted of the following: (In thousands) September 30, December 31, Brand name and trademark (life indefinite) of discontinued operations $ — $ 1,510 Purchased technology (5-17 year lives) $ 1,447 $ 1,401 Purchased technology (5-17 year lives) of discontinued operations, net — 112 Less: accumulated amortization (1,415 ) (1,334 ) Purchased technology, net $ 32 $ 179 Goodwill $ 185 $ 185 The Bovie brand name and trademarks were included in the definitive asset purchase agreement with Specialty Surgical Instrumentation Inc., as previously disclosed. Goodwill results from our acquisition of Bovie Bulgaria, EOOD. Amortization of purchased technology was $27,000 and $81,000 for the three and nine months ended September 30, 2018 and 2017 , respectively. Amortization expense is classified within selling, general and administration expenses in the consolidated statements of operations.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment . The purpose of this ASU is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this ASU, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit’s fair value. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted, however we have chosen not to do so. The amendment is not expected to have a material impact on our financial condition or results of operations. ASU No. 2016-18, Restricted Cash Flows provides guidance on the presentation of restricted cash and restricted cash equivalents, which are now included with cash and cash equivalents when reconciling the beginning and ending cash amounts shown on the statements of cash flows. Using the retrospective transition method required under the standard, the Company has adjusted the presentation of its Condensed Consolidated Statements of Cash Flows for all periods presented. The adoption of ASU No. 2016-18 did not have any other impact on the Company’s Consolidated Financial Statements. The following table provides additional detail by financial statement line item of the ASU 2016-18 impact in our Consolidated Statement of Cash Flows for the nine months ended September 30, 2017 : (In thousands) As Reported (Pre-Adoption) ASU 2016-18 Reported (Post Adoption) Nine Months Ended September 30, 2017 Net change in cash, cash equivalents and restricted cash $ (5,045 ) $ — $ (5,045 ) Cash, cash equivalents and restricted cash, beginning of period 14,456 779 15,235 Cash, cash equivalents and restricted cash, end of period $ 9,411 $ 779 $ 10,190 ASU No. 2014-09 (ASC 606), Revenue from Contracts with Customers became effective for us beginning with the first quarter of 2018, and adopted the new accounting standard using the modified retrospective transition approach. The modified retrospective transition approach recognized any changes from the beginning of the year of initial application through retained earnings with no restatement of comparative periods. We record revenue under ASC 606 at a single point in time, when control is transferred to the customer, which is consistent with past practice. We will continue to apply our current business processes, policies, systems and controls to support recognition and disclosure under the new standard. Based on the results of the evaluation, we have determined that the adoption of the new standard presents no material impact on our consolidated financial statements. Application of the transition requirements of the new standard did not have a material impact on opening retained earnings. We have disaggregated revenue by segment and geography in Note 14 Geographic and Segment Information. Based on the current state of our business, management does not see a material reason to disaggregate further. No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.

EARNINGS PER SHARE

EARNINGS PER SHARE	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE We compute basic earnings per share (“basic EPS”) by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding. The following table provides the computation of basic and diluted earnings per share. Three Months Ended Nine Months Ended (in thousands, except per share data) 2018 as Restated 2017 2018 as Restated 2017 Numerator: Net loss from continuing operations $ (1,143 ) $ (2,944 ) $ (6,872 ) $ (10,709 ) Total income from discontinued operations, net of tax 69,612 1,699 74,134 6,471 Net income (loss) $ 68,469 $ (1,245 ) $ 67,262 $ (4,238 ) Denominator: Weighted average shares used to compute basic income (loss) 33,275 31,078 33,014 30,932 Effect of dilutive securities: Stock options 1,659 — 938 — Denominator for dilutive income (loss) per share 34,934 31,078 33,952 30,932 Loss per share from continuing operations Basic $ (0.03 ) $ (0.09 ) $ (0.21 ) $ (0.35 ) Diluted $ (0.03 ) $ (0.09 ) $ (0.21 ) $ (0.35 ) Income per share from discontinued operations Basic $ 2.09 $ 0.05 $ 2.25 $ 0.21 Diluted $ 1.99 $ 0.05 $ 2.19 $ 0.21 Income (loss) per share Basic $ 2.06 $ (0.04 ) $ 2.04 $ (0.14 ) Diluted $ 1.96 $ (0.04 ) $ 1.98 $ (0.14 ) Anti-dilutive instruments excluded from diluted loss per common share: Warrants — 7 — 13 Options — 373 — 771

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2018
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION Under our stock option plans, our board of directors may grant options to purchase common shares to our key employees, officers, directors and consultants. We account for stock options in accordance with FASB ASC Topic 718, Compensation - Stock Compensation , with option expense amortized over the vesting period based on the trinomial lattice option-pricing model fair value on the grant date, which includes a number of estimates that affect the amount of our expense. We expensed approximately $489,000 and $1,238,000 in stock-based compensation during the three and nine months ended September 30, 2018 , respectively, as compared with $191,000 and $532,000 for the three and nine months ended September 30, 2017 , respectively. The status of our stock options and stock awards are summarized as follows: Number of options - as Restated Weighted average exercise price - as Restated Outstanding at December 31, 2017 4,634,235 $ 3.10 Granted 225,000 4.08 Exercised (1,277,615 ) 2.43 Canceled and forfeited (225,841 ) 5.62 Outstanding at September 30, 2018 3,581,701 $ 3.25 Common shares required to be issued upon the exercise of stock options and warrants would be issued from our authorized and unissued shares. We calculated the fair value of issued options utilizing a trinomial lattice with an expected life calculated via the simplified method as we do not have sufficient history to determine actual expected life. 2018 Grants Option value $ 1.46 - $ 3.07 Risk-free rate 1.9% - 2.5 % Expected dividend yield — Expected volatility 60.9% - 68.8 % Expected term (in years) 6

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company’s income tax benefit from continuing operations was $2.4 million and $2.4 million with an effective tax rate of 67.8% and 25.8% for the three and nine months ended September 30, 2018 , respectively, as compared to an expense of $6,000 and $15,000 with an effective tax rate of 0.0% for the three and nine months ended September 30, 2017 , respectively. The increase in the Company’s tax rate for the three and nine months ended September 30, 2018 as compared to the three months and nine months ended September 30, 2017 , is primarily due to the Company’s ability to offset the 2018 operating loss from continuing operations against the taxable income generated by the extraordinary gain recognized by the income and asset sale reflected in discontinued operations. The Company recognized tax expense of $0.3 million and $1.2 million within net income from discontinued operations for the three and nine months ended September 30, 2018 , respectively. The Company recognized tax expense of $13.2 million and $15.5 million within the gain on sale of the Core Business for the three and nine months ended September 30, 2018 , respectively. Management expects the gain from the sale of the Core business segment to Symmetry will utilize substantially all of the historical Federal net operating loss carryover of $24.7 million , state(s) net operating loss carryover of $21.2 million , and research and development credit carryover of $1.3 million . As a result, the valuation allowance on these deferred tax assets was released during the third quarter of 2018 and the Company recorded a tax benefit of $7.8 million from the release of the valuation allowance. The tax benefit of $7.8 million is netted against the tax expenses within net income from discontinued operations and within the gain from asset sales. Pursuant to guidance under ASC 740, for the nine months ended September 30, 2018, continuing operations includes a current benefit of $2.4 million , which reflects the Company’s ability to fully utilize the net operating loss expected to be generated from continuing operations in the 2018 tax year. As a result of historical losses, exclusive of discontinued operations, the Company recorded a valuation allowance on the net deferred tax asset with a finite life and does not anticipate recording an income tax benefit related to these deferred tax assets beyond the 2018 tax year. The Company will reassess the realization of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent the financial results of continuing operations improve and it becomes more likely than not that the deferred tax assets will be realizable. As Management expects the Company to continue to generate loss in the foreseeable future after 2018, the Company will continue to record a valuation allowance on the remaining deferred tax assets at the end of 2018.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Property and Rental Agreements In March 2014, we signed a lease for offices located in Purchase, New York. In December 2017, we decided to consolidate operations in the Purchase, NY office with the facility in Clearwater, Florida. Based on this, we determined the office in Purchase, NY was no longer necessary and decided to cease all activity at the location. In August 2018 we negotiated a termination of the remainder of the lease, releasing us from any future obligation. In October 2015, pursuant to our acquisition of Bovie Bulgaria, we are obligated to pay a lease of $5,980 per month, expiring in December 2021, for 18,745 square feet of office, research and manufacturing space in Sofia, Bulgaria. The following is a schedule of approximate future minimum lease payments under operating leases as of September 30, 2018 : (In thousands) 2018 (remaining three months) $ 18 2019 72 2020 72 2021 72 Total $ 234 On August 30, 2018, the Company paid the remaining mortgage balance of $2.5 million , releasing us from any and all obligations to the Bank of Tampa. Litigation The medical device industry is characterized by frequent claims and litigation, and we are and may become subject to various claims, lawsuits and proceedings in the ordinary course of our business, including claims by current or former employees, distributors and competitors, and with respect to our products and product liability claims, lawsuits and proceedings. We are involved in a number of legal actions relating to the use of our J-Plasma technology. The outcomes of these legal actions are not within our complete control and may not be known for prolonged periods of time. In the opinion of management, the Company has meritorious defenses, and such claims are adequately covered by insurance, or are not expected, individually or in the aggregate, to result in a material, adverse effect on our financial condition. However, in the event that damages exceed the aggregate coverage limits of our policy or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with these claims could have a material adverse impact on our consolidated earnings, financial position or cash flows. Purchase Commitments At September 30, 2018 , we had purchase commitments for inventories totaling approximately $5.4 million , substantially all of which is expected to be purchased by the end of 2018 . Our manufacturing services agreements requires Symmetry to provide us with a twelve-month rolling production forecast, of which four months are binding, non-cancelable orders, subject to certain termination rights.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS Several relatives of Nikolay Shilev, Bovie Bulgaria’s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev’s spouse, is an employee of the Company working in the Accounting department. Antoaneta Dimitrova Shileva-Toromanova, Mr. Shilev’s sister, is the Manager of Production and Human Resources. Svetoslav Shilev, Mr. Shilev’s son, is an Engineer in the Quality Assurance department.

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS	9 Months Ended
	Sep. 30, 2018
Investments, Debt and Equity Securities [Abstract]
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	FINANCIAL INSTRUMENTS Cash, Cash Equivalents and Marketable Securities: (In thousands) Adjusted Cost Unrealized Gains Fair Value (3) Cash and Cash Equivalents (1) Short-term Marketable Securities Cash $ 5,774 $ — $ 5,774 $ 5,774 $ — Level 1 (2) U.S. Treasury Securities, maturities less than three months $ 34,889 $ — $ 34,889 $ 34,889 $ — U.S. Treasury Securities, maturities greater than three months $ 55,433 $ 47 $ 55,480 $ — $ 55,480 Total $ 96,096 $ 47 $ 96,143 $ 40,663 $ 55,480 (1) The company considers all highly liquid instruments with maturities of three months or less at the time of purchase to be cash equivalents. (2) The fair value of the debt securities consisting of U.S. Treasury bills is based on their quoted market prices. The fair value of these financial instruments are classified as Level 1 in the fair value hierarchy. (3) ASC 825-10, Financial Instruments , allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. At the date of purchase, the Company elected the fair value option for all investments with maturities of three months or greater at the time of purchase.

LONG TERM DEBT

LONG TERM DEBT	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
LONG TERM DEBT	LONG TERM DEBT On June 28, 2016, the Company entered into a transaction with Bank of Tampa, a Florida banking corporation (“Lender”), wherein Lender amended the terms of a mortgage loan (“the Loan”) originally executed on March 20, 2014 with a principal amount of $3,592,000 . The Initial Maturity Date of the Loan was extended to July 20, 2019 from March 19, 2017, and the Extended Maturity Date was amended to July 20, 2024 from March 20, 2022. On August 30, 2018, the Company paid the remaining mortgage balance of $2.5 million , releasing us from any and all obligations to the Bank of Tampa.

GEOGRAPHIC AND SEGMENT INFORMAT

GEOGRAPHIC AND SEGMENT INFORMATION	9 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
GEOGRAPHIC AND SEGMENT INFORMATION	GEOGRAPHIC AND SEGMENT INFORMATION Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, we also consider the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to our chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Our reportable segments are disclosed as principally organized and managed as three operating segments: Advanced Energy, OEM and Corporate & Other. The Corporate & Other category includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. Net assets are shared, therefore, not allocated to the reportable segments. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred. Summarized financial information with respect to reportable segments is as follows: Three Months Ended September 30, 2018 - as Restated (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 2,985 $ 687 $ — $ 3,672 (Loss) income from operations (1,155 ) 368 (2,001 ) (2,788 ) Interest income, net — — 105 105 Other losses — — (868 ) (868 ) Income tax benefit — — (2,408 ) (2,408 ) Depreciation and amortization — — 58 58 Three Months Ended September 30, 2017 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 2,126 $ 525 $ — $ 2,651 (Loss) income from operations (718 ) 323 (2,438 ) (2,833 ) Interest expense, net — — (36 ) (36 ) Change in fair value of derivative liabilities — — (69 ) (69 ) Income tax expense — — 6 6 Depreciation and amortization — — 171 171 Nine Months Ended September 30, 2018 - as Restated (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 8,727 $ 2,033 $ — $ 10,760 (Loss) income from operations (2,525 ) 1,076 (6,992 ) (8,441 ) Interest income, net — — 33 33 Other losses — — (868 ) (868 ) Change in fair value of derivative liabilities — — 20 20 Income tax expense — — (2,384 ) (2,384 ) Depreciation and amortization — — 429 429 Nine Months Ended September 30, 2017 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 4,546 $ 2,030 $ — $ 6,576 (Loss) income from operations (3,821 ) 1,031 (7,858 ) (10,648 ) Interest expense, net — — (103 ) (103 ) Change in fair value of derivative liabilities — — 57 57 Income tax expense — — 15 15 Depreciation and amortization — — 527 527 International sales represented approximately 24.8% and 21.2% of total revenues for the three and nine months ended September 30, 2018 , respectively, as compared with 16.6% and 11.5% of total revenues for the three and nine months ended September 30, 2017 , respectively. Substantially all of these sales are denominated in U.S. dollars. Revenue by geographic region, based on the “ship to” location on the invoice, are as follows: Three Months Ended Nine Months Ended (In thousands) 2018 2017 2018 2017 Sales by Domestic and International Domestic $ 2,763 $ 2,212 $ 8,481 $ 5,821 International 909 439 2,279 755 Total $ 3,672 $ 2,651 $ 10,760 $ 6,576

JOINT AND SEVERAL PAYROLL LIABI

JOINT AND SEVERAL PAYROLL LIABILITY	9 Months Ended
	Sep. 30, 2018
Other Liabilities Disclosure [Abstract]
Joint and Several Payroll Liability	JOINT AND SEVERAL PAYROLL LIABILITY As discussed in the Restatement Note (2), the Company did not report the correct amount of income to employees, nor did we collect and remit the employees' portion of income and payroll taxes, related to stock option exercises as required by the IRS. Due to IRS statutory requirements, we have joint and several liability for the full amount that was not withheld and remitted to the proper taxing authorities. This amount of the liability was approximately $0.7 million at September 30, 2018. The Company has recognized these amounts in other losses in the accompanying Consolidated Statements of Operations. If we can establish that our employees have in fact paid these obligations, either presently or in the future, we will be relieved of our liability.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Inventories	Inventories are stated at the lower of cost or market. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are allocated to inventory manufactured in-house based upon labor hours.
Recent Accounting Pronouncements	In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment . The purpose of this ASU is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this ASU, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit’s fair value. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted, however we have chosen not to do so. The amendment is not expected to have a material impact on our financial condition or results of operations. ASU No. 2016-18, Restricted Cash Flows provides guidance on the presentation of restricted cash and restricted cash equivalents, which are now included with cash and cash equivalents when reconciling the beginning and ending cash amounts shown on the statements of cash flows. Using the retrospective transition method required under the standard, the Company has adjusted the presentation of its Condensed Consolidated Statements of Cash Flows for all periods presented. The adoption of ASU No. 2016-18 did not have any other impact on the Company’s Consolidated Financial Statements. The following table provides additional detail by financial statement line item of the ASU 2016-18 impact in our Consolidated Statement of Cash Flows for the nine months ended September 30, 2017 : (In thousands) As Reported (Pre-Adoption) ASU 2016-18 Reported (Post Adoption) Nine Months Ended September 30, 2017 Net change in cash, cash equivalents and restricted cash $ (5,045 ) $ — $ (5,045 ) Cash, cash equivalents and restricted cash, beginning of period 14,456 779 15,235 Cash, cash equivalents and restricted cash, end of period $ 9,411 $ 779 $ 10,190 ASU No. 2014-09 (ASC 606), Revenue from Contracts with Customers became effective for us beginning with the first quarter of 2018, and adopted the new accounting standard using the modified retrospective transition approach. The modified retrospective transition approach recognized any changes from the beginning of the year of initial application through retained earnings with no restatement of comparative periods. We record revenue under ASC 606 at a single point in time, when control is transferred to the customer, which is consistent with past practice. We will continue to apply our current business processes, policies, systems and controls to support recognition and disclosure under the new standard. Based on the results of the evaluation, we have determined that the adoption of the new standard presents no material impact on our consolidated financial statements. Application of the transition requirements of the new standard did not have a material impact on opening retained earnings. We have disaggregated revenue by segment and geography in Note 14 Geographic and Segment Information. Based on the current state of our business, management does not see a material reason to disaggregate further. No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.

RESTATEMENT (Tables)

RESTATEMENT (Tables)	9 Months Ended
	Sep. 30, 2018
Accounting Changes and Error Corrections [Abstract]
Summary of Restatements	Consolidated Balance Sheet as of September 30, 2018: (In thousands) As Originally Reported Adjustments As Restated ASSETS Current assets: Cash and cash equivalents $ 40,663 $ — $ 40,663 Short term investments 55,480 — 55,480 Trade accounts receivable, net 4,080 59 4,139 Inventories, net 6,037 — 6,037 Prepaid expenses and other current assets 627 — 627 Total current assets 106,887 59 106,946 Property and equipment, net 5,842 — 5,842 Purchased technology and license rights, net 32 — 32 Goodwill 185 — 185 Deposits 46 — 46 Other assets 122 — 122 Total assets $ 113,114 $ 59 $ 113,173 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 2,348 $ — $ 2,348 Accrued severance and related 95 — 95 Accrued payroll 163 — 163 Accrued expenses and other current liabilities 19,066 764 19,830 Total current liabilities 21,672 764 22,436 Related party note payable 140 — 140 Total liabilities 21,812 764 22,576 STOCKHOLDERS' EQUITY Common stock, $0.001 par value; 75,000,000 shares authorized; 33,763,019 issued and 33,620,444 outstanding 33 — 33 Additional paid-in capital 51,798 — 51,798 Retained earnings 39,471 (705 ) 38,766 Total stockholders’ equity 91,302 (705 ) 90,597 Total liabilities and stockholders’ equity $ 113,114 $ 59 $ 113,173 Consolidated Statement of Operations for the three months ended September 30, 2018: (In thousands) As Originally Reported Adjustments As Restated Sales $ 3,672 $ — $ 3,672 Cost of sales 1,151 — 1,151 Gross profit 2,521 — 2,521 Other costs and expenses: Research and development 613 — 613 Professional services 628 — 628 Salaries and related costs 2,119 51 2,170 Selling, general and administrative 1,957 (59 ) 1,898 Total other costs and expenses 5,317 (8 ) 5,309 Loss from operations (2,796 ) 8 (2,788 ) Interest income (expense), net 105 — 105 Other losses (155 ) (713 ) (868 ) Total other losses, net (50 ) (713 ) (763 ) Loss from continuing operations before income taxes (2,846 ) (705 ) (3,551 ) Income tax benefit (2,408 ) — (2,408 ) Net loss from continuing operations (438 ) (705 ) (1,143 ) Income from discontinued operations, net of tax 540 — 540 Gain on sale of the Core Business, net of tax 69,072 — 69,072 Total income from discontinued operations, net of tax 69,612 — 69,612 Net income (loss) $ 69,174 $ (705 ) $ 68,469 Loss per share from continuing operations Basic and Diluted $ (0.01 ) $ (0.02 ) $ (0.03 ) Income per share from discontinued operations Basic 2.09 — 2.09 Diluted 1.99 — 1.99 Income (loss) per share from all operations Basic 2.08 (0.02 ) 2.06 Diluted 1.98 (0.02 ) 1.96 Weighted average number of shares outstanding basic 33,275 33,275 33,275 Weighted average number of shares outstanding diluted 34,934 34,934 34,934 Consolidated Statement of Operations for the nine months ended September 30, 2018: (In thousands) As Originally Reported Adjustments As Restated Sales $ 10,760 $ — $ 10,760 Cost of sales 3,490 — 3,490 Gross profit 7,270 — 7,270 Other costs and expenses: Research and development 1,890 — 1,890 Professional services 1,815 — 1,815 Salaries and related costs 5,734 51 5,785 Selling, general and administrative 6,280 (59 ) 6,221 Total other costs and expenses 15,719 (8 ) 15,711 Loss from operations (8,449 ) 8 (8,441 ) Interest income (expense), net 33 — 33 Other losses (155 ) (713 ) (868 ) Change in fair value of derivative liabilities 20 — 20 Total other losses, net (102 ) (713 ) (815 ) Loss from continuing operations before income taxes (8,551 ) (705 ) (9,256 ) Income tax benefit (2,384 ) — (2,384 ) Net loss from continuing operations (6,167 ) (705 ) (6,872 ) Income from discontinued operations, net of tax 5,062 — 5,062 Gain on sale of the Core Business, net of tax 69,072 — 69,072 Total income from discontinued operations, net of tax 74,134 — 74,134 Net income (loss) $ 67,967 $ (705 ) $ 67,262 Loss per share from continuing operations Basic and Diluted $ (0.19 ) $ (0.02 ) $ (0.21 ) Income per share from discontinued operations Basic 2.25 — 2.25 Diluted 2.19 — 2.19 Income (loss) per share from all operations Basic 2.06 (0.02 ) 2.04 Diluted 2.00 (0.02 ) 1.98 Weighted average number of shares outstanding basic 33,014 33,014 33,014 Weighted average number of shares outstanding diluted 33,952 33,952 33,952

BASIS OF PRESENTATION (Tables)

BASIS OF PRESENTATION (Tables)	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
New accounting pronouncement, early adoption	The following table provides additional detail by financial statement line item of the ASU 2016-18 impact in our Consolidated Statement of Cash Flows for the nine months ended September 30, 2017 : (In thousands) As Reported (Pre-Adoption) ASU 2016-18 Reported (Post Adoption) Nine Months Ended September 30, 2017 Net change in cash, cash equivalents and restricted cash $ (5,045 ) $ — $ (5,045 ) Cash, cash equivalents and restricted cash, beginning of period 14,456 779 15,235 Cash, cash equivalents and restricted cash, end of period $ 9,411 $ 779 $ 10,190

DISPOSITION OF THE CORE BUSIN_2

DISPOSITION OF THE CORE BUSINESS (Tables)	9 Months Ended
	Sep. 30, 2018
Discontinued Operations and Disposal Groups [Abstract]
Cash consideration and fair value of assets disposed	The table below summarizes the cash consideration and the carrying values of disposed assets at the disposition date of August 30, 2018 included as part of discontinued operations: (In thousands) Gross consideration from the sale of the Core Business $ 97,000 Closing and transaction costs 5,905 Net proceeds from sale of the Core Business before taxes $ 91,095 Book value of the Core Business Current assets: Inventories, net 2,195 Prepaid expenses and other current assets 57 Total current assets 2,252 Property and equipment, net of depreciation 375 Brand name and trademark 1,510 Purchased technology and license rights, net of depreciation 112 Total non-current assets 1,997 Total assets $ 4,249 Current liabilities: Accrued inventory liability 2,305 Total current liabilities 2,305 Total book value of the Core Business $ 6,554 Net gain on sale of the Core Business before taxes 84,541 Income tax expense 15,469 Net gain on sale of the Core Business after income taxes $ 69,072
Operating activity related to the Core business	The table below summarizes the cash consideration and the carrying values of disposed assets at the disposition date of August 30, 2018 included as part of discontinued operations: (In thousands) Gross consideration from the sale of the Core Business $ 97,000 Closing and transaction costs 5,905 Net proceeds from sale of the Core Business before taxes $ 91,095 Book value of the Core Business Current assets: Inventories, net 2,195 Prepaid expenses and other current assets 57 Total current assets 2,252 Property and equipment, net of depreciation 375 Brand name and trademark 1,510 Purchased technology and license rights, net of depreciation 112 Total non-current assets 1,997 Total assets $ 4,249 Current liabilities: Accrued inventory liability 2,305 Total current liabilities 2,305 Total book value of the Core Business $ 6,554 Net gain on sale of the Core Business before taxes 84,541 Income tax expense 15,469 Net gain on sale of the Core Business after income taxes $ 69,072

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Schedule of inventory	Inventories consisted of the following: (In thousands) September 30, December 31, Raw materials $ 5,032 $ 5,163 Finished goods 1,998 1,024 Gross inventories 7,030 6,187 Less: reserve for obsolescence (993 ) (1,913 ) Net inventories of continuing operations 6,037 4,274 Finished goods of discontinued operations — 2,252 Net inventories of continuing and discontinued operations $ 6,037 $ 6,526

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	Intangible assets consisted of the following: (In thousands) September 30, December 31, Brand name and trademark (life indefinite) of discontinued operations $ — $ 1,510 Purchased technology (5-17 year lives) $ 1,447 $ 1,401 Purchased technology (5-17 year lives) of discontinued operations, net — 112 Less: accumulated amortization (1,415 ) (1,334 ) Purchased technology, net $ 32 $ 179 Goodwill $ 185 $ 185

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Basic and diluted earnings per share	The following table provides the computation of basic and diluted earnings per share. Three Months Ended Nine Months Ended (in thousands, except per share data) 2018 as Restated 2017 2018 as Restated 2017 Numerator: Net loss from continuing operations $ (1,143 ) $ (2,944 ) $ (6,872 ) $ (10,709 ) Total income from discontinued operations, net of tax 69,612 1,699 74,134 6,471 Net income (loss) $ 68,469 $ (1,245 ) $ 67,262 $ (4,238 ) Denominator: Weighted average shares used to compute basic income (loss) 33,275 31,078 33,014 30,932 Effect of dilutive securities: Stock options 1,659 — 938 — Denominator for dilutive income (loss) per share 34,934 31,078 33,952 30,932 Loss per share from continuing operations Basic $ (0.03 ) $ (0.09 ) $ (0.21 ) $ (0.35 ) Diluted $ (0.03 ) $ (0.09 ) $ (0.21 ) $ (0.35 ) Income per share from discontinued operations Basic $ 2.09 $ 0.05 $ 2.25 $ 0.21 Diluted $ 1.99 $ 0.05 $ 2.19 $ 0.21 Income (loss) per share Basic $ 2.06 $ (0.04 ) $ 2.04 $ (0.14 ) Diluted $ 1.96 $ (0.04 ) $ 1.98 $ (0.14 ) Anti-dilutive instruments excluded from diluted loss per common share: Warrants — 7 — 13 Options — 373 — 771

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2018
Share-based Payment Arrangement [Abstract]
Summary of stock options and stock awards	The status of our stock options and stock awards are summarized as follows: Number of options - as Restated Weighted average exercise price - as Restated Outstanding at December 31, 2017 4,634,235 $ 3.10 Granted 225,000 4.08 Exercised (1,277,615 ) 2.43 Canceled and forfeited (225,841 ) 5.62 Outstanding at September 30, 2018 3,581,701 $ 3.25
Schedule of option fair value assumptions	2018 Grants Option value $ 1.46 - $ 3.07 Risk-free rate 1.9% - 2.5 % Expected dividend yield — Expected volatility 60.9% - 68.8 % Expected term (in years) 6

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Future minimum lease payments under operating leases	The following is a schedule of approximate future minimum lease payments under operating leases as of September 30, 2018 : (In thousands) 2018 (remaining three months) $ 18 2019 72 2020 72 2021 72 Total $ 234

FINANCIAL INSTRUMENTS (Tables)

FINANCIAL INSTRUMENTS (Tables)	9 Months Ended
	Sep. 30, 2018
Investments, Debt and Equity Securities [Abstract]
Cash, Cash Equivalents and Investments	Cash, Cash Equivalents and Marketable Securities: (In thousands) Adjusted Cost Unrealized Gains Fair Value (3) Cash and Cash Equivalents (1) Short-term Marketable Securities Cash $ 5,774 $ — $ 5,774 $ 5,774 $ — Level 1 (2) U.S. Treasury Securities, maturities less than three months $ 34,889 $ — $ 34,889 $ 34,889 $ — U.S. Treasury Securities, maturities greater than three months $ 55,433 $ 47 $ 55,480 $ — $ 55,480 Total $ 96,096 $ 47 $ 96,143 $ 40,663 $ 55,480 (1) The company considers all highly liquid instruments with maturities of three months or less at the time of purchase to be cash equivalents. (2) The fair value of the debt securities consisting of U.S. Treasury bills is based on their quoted market prices. The fair value of these financial instruments are classified as Level 1 in the fair value hierarchy. (3) ASC 825-10, Financial Instruments , allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. At the date of purchase, the Company elected the fair value option for all investments with maturities of three months or greater at the time of purchase.

GEOGRAPHIC AND SEGMENT INFORM_2

GEOGRAPHIC AND SEGMENT INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Schedule of reporting information by segment	Summarized financial information with respect to reportable segments is as follows: Three Months Ended September 30, 2018 - as Restated (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 2,985 $ 687 $ — $ 3,672 (Loss) income from operations (1,155 ) 368 (2,001 ) (2,788 ) Interest income, net — — 105 105 Other losses — — (868 ) (868 ) Income tax benefit — — (2,408 ) (2,408 ) Depreciation and amortization — — 58 58 Three Months Ended September 30, 2017 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 2,126 $ 525 $ — $ 2,651 (Loss) income from operations (718 ) 323 (2,438 ) (2,833 ) Interest expense, net — — (36 ) (36 ) Change in fair value of derivative liabilities — — (69 ) (69 ) Income tax expense — — 6 6 Depreciation and amortization — — 171 171 Nine Months Ended September 30, 2018 - as Restated (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 8,727 $ 2,033 $ — $ 10,760 (Loss) income from operations (2,525 ) 1,076 (6,992 ) (8,441 ) Interest income, net — — 33 33 Other losses — — (868 ) (868 ) Change in fair value of derivative liabilities — — 20 20 Income tax expense — — (2,384 ) (2,384 ) Depreciation and amortization — — 429 429 Nine Months Ended September 30, 2017 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 4,546 $ 2,030 $ — $ 6,576 (Loss) income from operations (3,821 ) 1,031 (7,858 ) (10,648 ) Interest expense, net — — (103 ) (103 ) Change in fair value of derivative liabilities — — 57 57 Income tax expense — — 15 15 Depreciation and amortization — — 527 527
Schedule of revenue by geographic area	Revenue by geographic region, based on the “ship to” location on the invoice, are as follows: Three Months Ended Nine Months Ended (In thousands) 2018 2017 2018 2017 Sales by Domestic and International Domestic $ 2,763 $ 2,212 $ 8,481 $ 5,821 International 909 439 2,279 755 Total $ 3,672 $ 2,651 $ 10,760 $ 6,576

RESTATEMENT Narrative (Details)

RESTATEMENT Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2018
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Operating expenses	$ 5,309	$ 4,746	$ 15,711	$ 14,910
Other losses, net	868	0	868	0
Net loss	(68,469)	1,245	(67,262)	4,238
Operating loss	2,788	$ 2,833	8,441	$ 10,648
Income Tax Provision Corrections | Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Operating expenses	51		51		$ 51
Other losses, net	713		713		713
Net loss	764		764		$ 764
Appropriate Cutoff Of Transactions Corrections | Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Operating expenses	59		59
Net loss	59		59
Operating loss	$ 59		$ 59

RESTATEMENT Consolidated Balanc

RESTATEMENT Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
ASSETS
Cash and cash equivalents	$ 40,663	$ 9,949
Short term investments	55,480	0
Trade accounts receivable, net	4,139	4,857
Inventories, net	6,037	4,274
Prepaid expenses and other current assets	627	433
Total current assets	106,946	22,547
Property and equipment, net	5,842	6,033
Purchased technology and license rights, net	32	67
Goodwill	185	185
Deposits	46	92
Other assets	122	67
Total assets	113,173	30,988
Current liabilities:
Accounts payable	2,348	1,583
Accrued severance and related	95	1,242
Accrued payroll	163	447
Accrued expenses and other current liabilities	19,830	214
Total current liabilities	22,436	5,973
Related party note payable	140	140
Total liabilities	22,576	8,956
STOCKHOLDERS' EQUITY
Common stock	33	33
Additional paid-in capital	51,798	50,495
Retained earnings	38,766	(28,496)
Total stockholders’ equity	90,597	22,032	$ 22,517	$ 26,223
Total liabilities and stockholders’ equity	113,173	$ 30,988
As Originally Reported
ASSETS
Cash and cash equivalents	40,663
Short term investments	55,480
Trade accounts receivable, net	4,080
Inventories, net	6,037
Prepaid expenses and other current assets	627
Total current assets	106,887
Property and equipment, net	5,842
Purchased technology and license rights, net	32
Goodwill	185
Deposits	46
Other assets	122
Total assets	113,114
Current liabilities:
Accounts payable	2,348
Accrued severance and related	95
Accrued payroll	163
Accrued expenses and other current liabilities	19,066
Total current liabilities	21,672
Related party note payable	140
Total liabilities	21,812
STOCKHOLDERS' EQUITY
Common stock	33
Additional paid-in capital	51,798
Retained earnings	39,471
Total stockholders’ equity	91,302
Total liabilities and stockholders’ equity	113,114
Adjustments | Material Corrections
ASSETS
Cash and cash equivalents	0
Short term investments	0
Trade accounts receivable, net	59
Inventories, net	0
Prepaid expenses and other current assets	0
Total current assets	59
Property and equipment, net	0
Purchased technology and license rights, net	0
Goodwill	0
Deposits	0
Other assets	0
Total assets	59
Current liabilities:
Accounts payable	0
Accrued severance and related	0
Accrued payroll	0
Accrued expenses and other current liabilities	764
Total current liabilities	764
Related party note payable	0
Total liabilities	764
STOCKHOLDERS' EQUITY
Common stock	0
Additional paid-in capital	0
Retained earnings	(705)
Total stockholders’ equity	(705)
Total liabilities and stockholders’ equity	$ 59

RESTATEMENT Consolidated Bala_2

RESTATEMENT Consolidated Balance Sheets - Additional Information (Details) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Accounting Changes and Error Corrections [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	33,763,019	33,021,170
Common stock, shares outstanding (in shares)	33,620,444	32,878,091

RESTATEMENT Consolidated Statem

RESTATEMENT Consolidated Statements of Operations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	Aug. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Sales		$ 3,672	$ 2,651	$ 10,760	$ 6,576
Cost of sales		1,151	738	3,490	2,314
Gross profit		2,521	1,913	7,270	4,262
Other costs and expenses:
Research and development		613	487	1,890	1,600
Professional services		628	421	1,815	1,291
Salaries and related costs		2,170	1,826	5,785	6,016
Selling, general and administrative		1,898	2,012	6,221	6,003
Total other costs and expenses		5,309	4,746	15,711	14,910
Loss from operations		(2,788)	(2,833)	(8,441)	(10,648)
Interest income (expense), net		105	(36)	33	(103)
Other losses, net		(868)	0	(868)	0
Change in fair value of derivative liabilities		0	(69)	20	57
Total other expense, net		(763)	(105)	(815)	(46)
Loss from continuing operations before income taxes		(3,551)	(2,938)	(9,256)	(10,694)
Income tax (benefit) expense		(2,408)	6	(2,384)	15
Net loss from continuing operations		(1,143)	(2,944)	(6,872)	(10,709)
Income from discontinued operations, net of tax		540	1,699	5,062	6,471
Gain on sale of the Core Business, net of tax	$ 69,072	69,072	0	69,072	0
Total income from discontinued operations, net of tax		69,612	1,699	74,134	6,471
Net income (loss)		$ 68,469	$ (1,245)	$ 67,262	$ (4,238)
Loss per share from continuing operations
Basic and diluted (in dollars per share)		$ (0.03)		$ (0.21)
Income per share from discontinued operations
Basic (in dollars per share)		2.09	$ 0.05	2.25	$ 0.21
Diluted (in dollars per share)		1.99	0.05	2.19	0.21
Income (loss) per share from all operations
Basic (in dollars per share)		2.06	(0.04)	2.04	(0.14)
Diluted (in dollars per share)		$ 1.96	$ (0.04)	$ 1.98	$ (0.14)
Weighted average number of shares outstanding basic (in shares)		33,275	31,078	33,014	30,932
Weighted average number of shares outstanding dilutive (in shares)		34,934	31,078	33,952	30,932
As Originally Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Sales		$ 3,672		$ 10,760
Cost of sales		1,151		3,490
Gross profit		2,521		7,270
Other costs and expenses:
Research and development		613		1,890
Professional services		628		1,815
Salaries and related costs		2,119		5,734
Selling, general and administrative		1,957		6,280
Total other costs and expenses		5,317		15,719
Loss from operations		(2,796)		(8,449)
Interest income (expense), net		105		33
Other losses, net		(155)		(155)
Change in fair value of derivative liabilities				20
Total other expense, net		(50)		(102)
Loss from continuing operations before income taxes		(2,846)		(8,551)
Income tax (benefit) expense		(2,408)		(2,384)
Net loss from continuing operations		(438)		(6,167)
Income from discontinued operations, net of tax		540		5,062
Gain on sale of the Core Business, net of tax		69,072		69,072
Total income from discontinued operations, net of tax		69,612		74,134
Net income (loss)		$ 69,174		$ 67,967
Loss per share from continuing operations
Basic and diluted (in dollars per share)		$ (0.01)		$ (0.19)
Income per share from discontinued operations
Basic (in dollars per share)		2.09		2.25
Diluted (in dollars per share)		1.99		2.19
Income (loss) per share from all operations
Basic (in dollars per share)		2.08		2.06
Diluted (in dollars per share)		$ 1.98		$ 2
Weighted average number of shares outstanding basic (in shares)		33,275		33,014
Weighted average number of shares outstanding dilutive (in shares)		34,934		33,952
Adjustments | Material Corrections
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Sales		$ 0		$ 0
Cost of sales		0		0
Gross profit		0		0
Other costs and expenses:
Research and development		0		0
Professional services		0		0
Salaries and related costs		51		51
Selling, general and administrative		(59)		(59)
Total other costs and expenses		(8)		(8)
Loss from operations		8		8
Interest income (expense), net		0		0
Other losses, net		(713)		(713)
Change in fair value of derivative liabilities				0
Total other expense, net		(713)		(713)
Loss from continuing operations before income taxes		(705)		(705)
Income tax (benefit) expense		0		0
Net loss from continuing operations		(705)		(705)
Income from discontinued operations, net of tax		0		0
Gain on sale of the Core Business, net of tax		0		0
Total income from discontinued operations, net of tax		0		0
Net income (loss)		$ (705)		$ (705)
Loss per share from continuing operations
Basic and diluted (in dollars per share)		$ (0.02)		$ (0.02)
Income per share from discontinued operations
Basic (in dollars per share)		0		0
Diluted (in dollars per share)		0		0
Income (loss) per share from all operations
Basic (in dollars per share)		(0.02)		(0.02)
Diluted (in dollars per share)		$ (0.02)		$ (0.02)
Weighted average number of shares outstanding basic (in shares)		33,275		33,014
Weighted average number of shares outstanding dilutive (in shares)		34,934		33,952

DISPOSITION OF THE CORE BUSIN_3

DISPOSITION OF THE CORE BUSINESS DISPOSITION OF THE CORE BUSINESS - NARRATIVE (Details) - USD ($) $ in Thousands	Aug. 30, 2018	Sep. 30, 2018	Sep. 30, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from the disposition of Core business	$ 97,000	$ 91,095	$ 0
Electro Surgical Disposables And Accessories, Cauteries And Other Products Supply Agreement | Symmetry Surgical Inc.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset purchase agreement, term		4 years
Manufacture And Supply Agreement | Symmetry Surgical Inc.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset purchase agreement, term		10 years

DISPOSITION OF THE CORE BUSIN_4

DISPOSITION OF THE CORE BUSINESS - CASH CONSIDERATION AND FAIR VALUE OF ASSETS DISPOSED (Details) - USD ($) $ in Thousands	Aug. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gross consideration from the sale of the Core Business	$ 97,000			$ 91,095	$ 0
Closing and transaction costs	5,905
Gross consideration from the sale of the Core Business	91,095
Core business disposition, current assets
Inventories, net	2,195	$ 0		0		$ 2,252
Prepaid expenses and other current assets	57
Total current assets	2,252	0		0		2,315
Property and equipment, net of depreciation	375
Non-current assets of discontinued operations	1,997	0		0		1,997
Total assets	4,249
Accrued inventory liability	2,305
Total current liabilities	2,305	0		0		$ 2,248
Total book value of the Core Business	6,554
Net gain on sale of the Core Business before taxes	(84,541)
Income tax expense, gain on disposal of the Core business	15,469	13,200		15,500
Gain on sale of the Core Business, net of tax	69,072	$ 69,072	$ 0	$ 69,072	$ 0
Purchased technology and license rights, net of depreciation
Core business disposition, current assets
Intangible assets	112
Brand name and trademark
Core business disposition, current assets
Intangible assets	$ 1,510

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Aug. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 5,032		$ 5,163
Finished goods	1,998		1,024
Gross inventories	7,030		6,187
Less: reserve for obsolescence	(993)		(1,913)
Net inventories of continuing and discontinued operations	6,037		4,274
Finished goods of discontinued operations	0	$ 2,195	2,252
Net inventories of continuing and discontinued operations	$ 6,037		$ 6,526

INTANGIBLE ASSETS (Details)

INTANGIBLE ASSETS (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Purchased technology	$ 1,447,000		$ 1,401,000
Purchased technology, net	32,000		67,000
Goodwill	185,000		185,000
Amortization of intangible assets	27,000	$ 81,000
Brand name and trademark
Indefinite-lived Intangible Assets [Line Items]
Brand name and trademark	0		1,510,000
Purchased technology and license rights
Finite-Lived Intangible Assets [Line Items]
Less: accumulated amortization	(1,415,000)		(1,334,000)
Purchased technology, net	$ 32,000		179,000
Purchased technology and license rights | Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life (in years)	5 years
Purchased technology and license rights | Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life (in years)	17 years
Purchased technology and license rights | Core
Finite-Lived Intangible Assets [Line Items]
Purchased technology	$ 0		$ 112,000
Purchased technology and license rights | Core | Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life (in years)	5 years
Purchased technology and license rights | Core | Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life (in years)	17 years

RECENT ACCOUNTING PRONOUNCEME_2

RECENT ACCOUNTING PRONOUNCEMENTS BASIS OF PRESENTATION (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
New Accounting Pronouncement, Early Adoption [Line Items]
Net change in cash, cash equivalents and restricted cash	$ 29,995	$ (5,045)
Cash, cash equivalents and restricted cash, beginning of period	10,668	15,235
Cash, cash equivalents and restricted cash, end of period	$ 40,663	10,190
Adjustments for New Accounting Principle, Early Adoption [Member]
New Accounting Pronouncement, Early Adoption [Line Items]
Net change in cash, cash equivalents and restricted cash		0
Cash, cash equivalents and restricted cash, beginning of period		779
Cash, cash equivalents and restricted cash, end of period		779
Previously reported
New Accounting Pronouncement, Early Adoption [Line Items]
Net change in cash, cash equivalents and restricted cash		(5,045)
Cash, cash equivalents and restricted cash, beginning of period		14,456
Cash, cash equivalents and restricted cash, end of period		$ 9,411

EARNINGS PER SHARE (Details)

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Numerator:
Net loss from continuing operations	$ 68,469	$ (1,245)	$ 67,262	$ (4,238)
Total income from discontinued operations, net of tax	69,612	1,699	74,134	6,471
Net income (loss)	$ 68,469	$ (1,245)	$ 67,262	$ (4,238)
Denominator:
Weighted average shares used to compute basic income (loss)	33,275	31,078	33,014	30,932
Effect of dilutive securities - stock options (in shares)	1,659	0	938	0
Denominator for dilutive income (loss) per share	34,934	31,078	33,952	30,932
Earnings per share, basic
Loss per share from continuing operations, basic	$ (0.03)	$ (0.09)	$ (0.21)	$ (0.35)
Income per share from discontinued operations, basic	2.09	0.05	2.25	0.21
Income (loss) per share, basic	2.06	(0.04)	2.04	(0.14)
Earnings per share, diluted
Loss per share from continuing operations, diluted	(0.03)	(0.09)	(0.21)	(0.35)
Income per share from discontinued operations, diluted	1.99	0.05	2.19	0.21
Income (loss) per share, diluted	$ 1.96	$ (0.04)	$ 1.98	$ (0.14)
Anti-dilutive securities excluded from diluted loss per share
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent	$ (1,143)	$ (2,944)	$ (6,872)	$ (10,709)
Warrants
Anti-dilutive securities excluded from diluted loss per share
Anti-dilutive securities excluded from diluted loss per share	0	7	0	13
Options
Anti-dilutive securities excluded from diluted loss per share
Anti-dilutive securities excluded from diluted loss per share	0	373	0	771

STOCK-BASED COMPENSATION - NARR

STOCK-BASED COMPENSATION - NARRATIVE (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-based Payment Arrangement [Abstract]
Stock based compensation	$ 489	$ 191	$ 1,238	$ 532

STOCK-BASED COMPENSATION - SUMM

STOCK-BASED COMPENSATION - SUMMARY OF STOCK OPTIONS (Details)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding, beginning of period (in shares) | shares	4,634,235
Granted (in shares) | shares	225,000
Exercised (in shares) | shares	(1,277,615)
Canceled and forfeited (in shares) | shares	(225,841)
Outstanding, end of period (in shares) | shares	3,581,701
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding, beginning of period (in dollars per share) | $ / shares	$ 3.10
Granted (in dollars per share) | $ / shares	4.08
Exercised (in dollars per share) | $ / shares	2.43
Canceled and forfeited (in dollars per shares) | $ / shares	5.62
Outstanding, end of period (in dollars per share) | $ / shares	$ 3.25

STOCK-BASED COMPENSATION - FAIR

STOCK-BASED COMPENSATION - FAIR VALUE ASSUMPTIONS (Details)	9 Months Ended
	Sep. 30, 2018$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield (as a percent)	0.00%
Expected term (in years)	6 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option value (in dollars per share)	$ 1.46
Risk-free rate (as a percent)	1.90%
Expected volatility (as a percent)	60.90%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option value (in dollars per share)	$ 3.07
Risk-free rate (as a percent)	2.50%
Expected volatility (as a percent)	68.80%

INCOME TAXES - EFFECTIVE TAX RA

INCOME TAXES - EFFECTIVE TAX RATE (Details) - USD ($) $ in Thousands	Aug. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Operating Loss Carryforwards [Line Items]
Income tax (benefit) expense		$ (2,408)	$ 6	$ (2,384)	$ 15
Effective income tax rate, percent (as a percent)		67.80%	0.00%	25.80%	0.00%
Income tax expense, discontinued operations		$ 300		$ 1,200
Income tax expense, gain on disposal of the Core business	$ 15,469	13,200		15,500
Tax credit carryforward, valuation allowance		7,800		7,800
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		24,700		24,700
State and Local Jurisdiction
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		21,200		21,200
Research and Development Tax Credit Carryforward
Operating Loss Carryforwards [Line Items]
Tax credit carryforward, amount		$ 1,300		$ 1,300

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - FUTURE MINIMUM LEASE PAYMENTS (Details) $ in Thousands	Sep. 30, 2018USD ($)
Future minimum lease payments under operating leases
2018 (remaining three months)	$ 18
2019	72
2020	72
2021	72
Total	$ 234

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES - NARRATIVE (Details)	9 Months Ended
	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Oct. 31, 2015USD ($)ft²
Other Commitments [Line Items]
Repayment of mortgage note payable	$ 2,694,000	$ 179,000
Purchase commitments for inventories	$ 5,400,000
Sophia, Bulgaria
Other Commitments [Line Items]
Area of real estate property (in square feet) | ft²			18,745
Monthly cost of office space			$ 5,980

FINANCIAL INSTRUMENTS (Details)

FINANCIAL INSTRUMENTS (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Debt Securities, Available-for-sale [Line Items]
Cash	$ 5,774
Adjusted Cost	96,096
Unrealized Gains	47
Fair Value	96,143
Short-term Marketable Securities	55,480	$ 0
Cash and cash equivalents	40,663	$ 9,949
U.S. Treasury Securities, maturities less than three months
Debt Securities, Available-for-sale [Line Items]
Adjusted Cost	34,889
Fair Value	34,889
Cash equivalents	34,889
U.S. Treasury Securities, maturities greater than three months
Debt Securities, Available-for-sale [Line Items]
Adjusted Cost	55,433
Unrealized Gains	47
Fair Value	55,480
Short-term Marketable Securities	$ 55,480

LONG TERM DEBT - NARRATIVE (Det

LONG TERM DEBT - NARRATIVE (Details) - USD ($) $ in Thousands	Aug. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Jun. 28, 2016
Debt Instrument [Line Items]
Repayment of mortgage note payable		$ 2,694	$ 179
Mortgages
Debt Instrument [Line Items]
Mortgage loan, principal amount				$ 3,592
Repayment of mortgage note payable	$ 2,500

GEOGRAPHIC AND SEGMENT INFORM_3

GEOGRAPHIC AND SEGMENT INFORMATION - REPORTABLE SEGMENT (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Segment Reporting Information [Line Items]
Sales	$ 3,672	$ 2,651	$ 10,760	$ 6,576
(Loss) income from operations	(2,788)	(2,833)	(8,441)	(10,648)
Interest income (expense), net	105	(36)	33	(103)
Other losses	(868)	0	(868)	0
Change in fair value of derivative liabilities	0	(69)	20	57
Income tax (benefit) expense	(2,408)	6	(2,384)	15
Depreciation and amortization	58	171	429	527
Operating Segments | Advanced Energy
Segment Reporting Information [Line Items]
Sales	2,985	2,126	8,727	4,546
(Loss) income from operations	(1,155)	(718)	(2,525)	(3,821)
Interest income (expense), net	0	0	0	0
Other losses	0		0
Change in fair value of derivative liabilities		0	0	0
Income tax (benefit) expense	0	0	0	0
Depreciation and amortization	0	0	0	0
Operating Segments | OEM
Segment Reporting Information [Line Items]
Sales	687	525	2,033	2,030
(Loss) income from operations	368	323	1,076	1,031
Interest income (expense), net	0	0	0	0
Other losses	0		0
Change in fair value of derivative liabilities		0	0	0
Income tax (benefit) expense	0	0	0	0
Depreciation and amortization	0	0	0	0
Corporate (Other)
Segment Reporting Information [Line Items]
Sales	0	0	0	0
(Loss) income from operations	(2,001)	(2,438)	(6,992)	(7,858)
Interest income (expense), net	105	(36)	33	(103)
Other losses	(868)		(868)
Change in fair value of derivative liabilities		(69)	20	57
Income tax (benefit) expense	(2,408)	6	(2,384)	15
Depreciation and amortization	$ 58	$ 171	$ 429	$ 527

GEOGRAPHIC AND SEGMENT INFORM_4

GEOGRAPHIC AND SEGMENT INFORMATION - GEOGRAPHIC (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Segment Reporting Information [Line Items]
Sales	$ 3,672	$ 2,651	$ 10,760	$ 6,576
Domestic
Segment Reporting Information [Line Items]
Sales	2,763	2,212	8,481	5,821
International
Segment Reporting Information [Line Items]
Sales	$ 909	$ 439	$ 2,279	$ 755

GEOGRAPHIC AND SEGMENT INFORM_5

GEOGRAPHIC AND SEGMENT INFORMATION - NARRATIVE (Details) - segment	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Segment Reporting [Abstract]
Number of operating segments (in segments)			3
Geographic concentration risk | Sales Revenue | International customers
Concentration Risk [Line Items]
Concentration receivable risk (as a percent)	24.80%	16.60%	21.20%	11.50%

JOINT AND SEVERAL PAYROLL LIA_2

JOINT AND SEVERAL PAYROLL LIABILITY (Details) $ in Millions	Sep. 30, 2018USD ($)
Other Liabilities Disclosure [Abstract]
Joint and several payroll liability	$ 0.7